STOCK TITAN
  1. Home
  2. Sec-filings
  3. CLLS
  4. [6-K] Cellectis S.A. Current Report (Foreign Issuer)

Cellectis to meet investors at 5 fall conferences

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Cellectis S.A. (CLLS), a clinical-stage gene-editing biotechnology company, reports that its management will participate in several upcoming healthcare investor conferences in the U.S. and Europe from September through November 2026. Events include conferences hosted by Wells Fargo, Baird, Barclays, Stifel and Jefferies in Boston, New York and London.

Cellectis’ team will be available for investor meetings at these events, coordinated either through conference organizers or the company’s Investor Relations. Any available webcasts of presentations will be posted in the events and webcasts section of Cellectis’ investor website.

Positive

  • None.

Negative

  • None.
Wells Fargo 21st Annual Healthcare Conference date September 10, 2026 Scheduled conference participation in Boston
Baird 2026 Global Healthcare Conference date September 15, 2026 Scheduled company presentation in New York
Barclays Biotech 1x1 Day date October 6, 2026 Fall Focus: Barclays Biotech 1x1 Day in New York
Stifel 2026 Healthcare Conference dates November 10-12, 2026 Planned participation in New York
Jefferies Global Healthcare Conference dates November 16-19, 2026 Planned participation in London
gene-editing platform medical
"a clinical-stage biotechnology company using its pioneering gene editing platform"
allogeneic approach medical
"The company utilizes an allogeneic approach for CAR T immunotherapies"
CAR T immunotherapies medical
"an allogeneic approach for CAR T immunotherapies in oncology"
off-the-shelf medical
"pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells"
Off-the-shelf describes products, software, medical devices, or solutions that are commercially available and ready to use without custom design or development. Investors care because off-the-shelf items typically cost less and reach the market faster than bespoke alternatives, reducing project risk and expense; like buying a ready-made appliance instead of commissioning a custom-built one, they offer predictable performance and clearer regulatory and cost forecasts.
in-house manufacturing capabilities technical
"With its in-house manufacturing capabilities, Cellectis is one of the few"

FAQ

What did Cellectis (CLLS) announce in this Form 6-K?
Cellectis announced that its management will participate in multiple healthcare investor conferences in Boston, New York and London between September and November 2026, with opportunities for investor meetings and potential webcasts posted on its investor events and webcasts webpage.

Which investor conferences will Cellectis (CLLS) attend and when?
Cellectis plans to attend the Wells Fargo 21st Annual Healthcare Conference on September 10, 2026; the Baird 2026 Global Healthcare Conference on September 15, 2026; Barclays Biotech 1x1 Day on October 6, 2026; the Stifel 2026 Healthcare Conference on November 10–12, 2026; and the Jefferies Global Healthcare Conference on November 16–19, 2026.

Will there be webcasts of Cellectis (CLLS) conference presentations?
Any available webcasts of Cellectis’ conference presentations will be posted on the company’s website in the investors section under “events and webcasts,” allowing interested parties to access recorded or live presentation content when provided.

How can investors arrange meetings with Cellectis (CLLS) management at these conferences?
Meetings with Cellectis’ management team can be arranged either through the respective conference representatives or by contacting Cellectis Investor Relations at the email address investors@cellectis.com as indicated in the announcement.

What kind of company is Cellectis (CLLS)?
Cellectis is a clinical-stage biotechnology company using a gene-editing platform to develop cell and gene therapies, including allogeneic CAR T immunotherapies as off-the-shelf, ready-to-use gene-edited CAR T-cells for oncology and a platform for gene therapies in other therapeutic indications.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

Date of Report: September 1, 2026

Commission File Number: 001-36891

Cellectis S.A.
(Exact Name of registrant as specified in its charter)

8, rue de la Croix Jarry
75013 Paris, France
+33 1 81 69 16 00
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

 

 

EXHIBIT INDEX

 

Exhibit Title
   
99.1 Press release, dated September 1, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

      Cellectis S.A.    
  (Registrant)
   
  
Date: September 1, 2026     /s/ André Choulika    
  André Choulika
  Chief Executive Officer
  

EXHIBIT 99.1

Cellectis Announces Participation in Upcoming Investor Conferences

NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today announced that it will participate in the upcoming investor conferences:

Wells Fargo 21st Annual Healthcare Conference – Boston, MA
September 10, 2026

Baird 2026 Global Healthcare Conference – New York
September 15, 2026
Company presentation at 12:50 - 1:20 p.m. ET

Fall Focus: Barclays Biotech 1x1 Day – New York
October 6, 2026

Stifel 2026 Healthcare Conference – New York
November 10-12, 2026

Jefferies Global Healthcare Conference – London
November 16-19, 2026

Cellectis' management team will be available for meetings with investors throughout these conferences. To arrange a meeting, please contact the respective conference representatives or Cellectis Investor Relations at investors@cellectis.com

Any available webcast will be posted to the Company's website at https://www.cellectis.com/en/investors/events-and-webcasts/.

About Cellectis     
Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company utilizes an allogeneic approach for CAR T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to develop gene therapies in other therapeutic indications. With its in-house manufacturing capabilities, Cellectis is one of the few end-to-end gene editing companies that controls the cell and gene therapy value chain from start to finish. Cellectis’ headquarters are in Paris, France, with locations in New York and Raleigh, NC. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more, visit www.cellectis.com and follow Cellectis on LinkedIn and X.

For further information on Cellectis, please contact:

Media contacts:
Pascalyne Wilson, Director, Communications, + 33 (0)7 76 99 14 33,

Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93, media@cellectis.com

Investor Relations contact:
Arthur Stril, Chief Financial Officer & Chief Business Officer, investors@cellectis.com

Attachment

  • PRESS RELEASE_Q4 2026 conference attendance_EN (https://ml.globenewswire.com/Resource/Download/2c87b37f-eaad-4e5a-9d0e-2c878845c025)

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

1 document

Press Releases